Your browser is no longer supported. Please, upgrade your browser.
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.01 Insider Own7.40% Shs Outstand47.93M Perf Week6.66%
Market Cap914.03M Forward P/E- EPS next Y-3.25 Insider Trans4.42% Shs Float44.37M Perf Month-10.93%
Income-218.20M PEG- EPS next Q-1.20 Inst Own74.10% Short Float45.98% Perf Quarter-2.31%
Sales1.30M P/S703.10 EPS this Y-53.40% Inst Trans22.80% Short Ratio2.72 Perf Half Y-51.25%
Book/sh3.04 P/B6.27 EPS next Y28.40% ROA-96.60% Target Price21.62 Perf Year-37.33%
Cash/sh2.70 P/C7.07 EPS next 5Y-0.20% ROE-141.30% 52W Range8.00 - 41.97 Perf YTD-50.57%
Dividend- P/FCF- EPS past 5Y0.00% ROI-103.00% 52W High-53.04% Beta1.65
Dividend %- Quick Ratio2.90 Sales past 5Y-46.80% Gross Margin- 52W Low146.37% ATR1.75
Employees270 Current Ratio2.90 Sales Q/Q- Oper. Margin- RSI (14)56.01 Volatility8.07% 8.78%
OptionableYes Debt/Eq0.15 EPS Q/Q12.20% Profit Margin- Rel Volume0.41 Prev Close19.07
ShortableYes LT Debt/Eq0.10 EarningsAug 04 BMO Payout- Avg Volume7.49M Price19.71
Recom2.70 SMA208.01% SMA5011.42% SMA200-17.06% Volume1,561,545 Change3.36%
Jun-09-16Upgrade Piper Jaffray Underweight → Neutral
Jun-07-16Upgrade Wedbush Neutral → Outperform $36
Jun-01-16Reiterated Wedbush Outperform $14 → $23
May-03-16Downgrade Leerink Partners Mkt Perform → Underperform
Apr-29-16Downgrade Jefferies Hold → Underperform
Apr-26-16Reiterated RBC Capital Mkts Sector Perform $7.50 → $5
Apr-26-16Reiterated Needham Buy $53 → $20
Apr-26-16Downgrade Sun Trust Rbsn Humphrey Neutral → Reduce
Apr-26-16Downgrade Piper Jaffray Neutral → Underweight
Apr-22-16Reiterated RBC Capital Mkts Sector Perform $14 → $7.50
Mar-23-16Downgrade JMP Securities Mkt Perform → Mkt Underperform
Mar-01-16Reiterated Needham Buy $55 → $53
Jan-19-16Downgrade RBC Capital Mkts Outperform → Sector Perform $62 → $15
Jan-15-16Downgrade Piper Jaffray Overweight → Neutral
Oct-23-15Resumed BofA/Merrill Buy
Oct-23-15Initiated Jefferies Hold $28
Oct-02-15Reiterated Needham Buy $38 → $55
Aug-26-15Reiterated ROTH Capital Buy $50 → $45
Aug-26-15Reiterated ROTH Capital Buy $45 → $50
Aug-24-15Upgrade Piper Jaffray Neutral → Overweight $28 → $48
Jul-01-16 06:00AM  'Mad Money' Lightning Round: You Should Be Buying Visa
Jun-30-16 06:21PM  141 Reasons to Love Biotech Stocks at Motley Fool
Jun-29-16 02:24PM  Behind the Recent Fall in BioMarins Premium Valuation
Jun-28-16 04:32PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +5.07%
09:39AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : June 28, 2016
Jun-27-16 04:35PM  Why Sarepta just made its soon-to-begin drug trial even longer at -8.48%
02:35PM  Still Little Hope Of FDA Approval For Sarepta, SunTrust Says Sell at
Jun-26-16 10:12AM  3 Tempting Stocks to Avoid at Motley Fool
Jun-23-16 03:50PM  Sarepta Therapeutics: Radio Silence at
03:07PM  Sarepta Push for Duchenne Drug Approval Helped by Clinical Trial Changes
Jun-21-16 07:01PM  Fake Tweets Sink Stocks: What Happens When Scammers Impersonate Research Firms at Motley Fool
02:27PM  Summit Therapeutics PLC (ADR) (SMMT) Is Hot On Sarepta Therapeutics Inc (SRPT)s DMD Tail at Insider Monkey
Jun-17-16 08:15AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : June 17, 2016
Jun-14-16 09:47AM  Sarepta seen holding onto recent gains
Jun-11-16 09:20AM  3 Biotechs That Just Announced Successful Phase 2 Trials at 24/7 Wall St.
Jun-10-16 04:34PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St
01:26PM  Sarepta Therapeutics: And Now We Wait at
01:15PM  4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
07:15AM  Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too
Jun-09-16 05:38PM  Why Envision Healthcare Holdings, Sarepta Therapeutics, and ABM Industries Jumped Today at Motley Fool +7.97%
04:10PM  Why Sarepta Therapeutics Shares Are Jumping 10% Today at Motley Fool
02:48PM  Sarepta (SRPT) Stock Spikes on $37.5 Million Stock Offering
02:11PM  Sarepta: Why So Little? at
11:59AM  Sarepta Therapeutics upgraded by Piper Jaffray
11:06AM  After recent stock surge, Sarepta looks to raise $38M in offering at
09:57AM  Sarepta Therapeutics: $5 Here We Come? at
07:00AM  Sarepta Therapeutics Announces Common Stock Offering Business Wire
Jun-08-16 04:19PM  Sarepta Therapeutics Announces Proposed Offering Business Wire
02:38PM  Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Jun-07-16 05:26PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +22.55%
04:43PM  Sarepta Stock Up On New Twist In Muscular-Dystrophy Drug Saga
01:16PM  Nobody Should Have Any Certainty About Sarepta at Forbes
12:13PM  Biotech stocks on the move
11:30AM  FDAs Woodcock: No connection between new drug access policy, Sarepta drug decision at
11:13AM  Valeant Pharmaceuticals tumbles; Ralph Lauren job cuts; Zillow to pay $130M to settle lawsuit
11:12AM  Why Sarepta Therapeutics Shares Skyrocketed Today at Motley Fool
10:44AM  What's driving Sarepta?
10:39AM  Sarepta: How Low is the FDA's Bar? at
10:10AM  Why Analysts Are Still All Over the Place on Sarepta After FDA News at 24/7 Wall St.
09:36AM  Stocks to Watch: LDR, Valeant, Sarepta, Biogen, TransUnion, Ralph Lauren at The Wall Street Journal
09:23AM  Sarepta Asked to Provide Dystrophin Data on Eteplirsen
08:50AM  Top Analyst Upgrades and Downgrades: First Data, GE, Sarepta, Western Digital, Walgreens, Zillow and More at 24/7 Wall St.
08:49AM  Morning Movers: Sarepta Surges on FDA Request; Valeant Plunges at
08:31AM  Why GE, Yahoo, and 3 Other Stocks Are Trending This Morning at Insider Monkey
08:02AM  Sarepta, FDA Compromise on Plan to Secure Duchenne Drug Approval
08:00AM  3 Stocks to Watch: June 7, 2016
Jun-06-16 07:31PM  [$$] Sarepta Shares Climb as FDA Requests Additional Information on Experimental Drug at The Wall Street Journal
05:40PM  Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA Business Wire
05:40PM  Biggest winners & losers from ASCO
05:14PM  Sarepta Therapeutics, Inc. Value Analysis (NASDAQ:SRPT) : June 6, 2016
12:17PM  Best bets in health care
Jun-05-16 10:05AM  5 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Jun-04-16 08:40AM  Why Sarepta Therapeutics Shares Skyrocketed 48% in May at Motley Fool
Jun-03-16 01:29PM  Sarepta Therapeutics: Bears are 'Fundamentally Wrong.' Here's Why. at
08:18AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : June 3, 2016
Jun-02-16 09:04PM  In wake of another delay, Duchenne advocates brace for longer wait at -26.62%
06:16PM  Sarepta sinks as FDA changes drug approval rules at CNBC
05:49PM  Why Sarepta Therapeutics, Signet Jewelers, and DeVry Education Group Slumped Today at Motley Fool
04:50PM  Sarepta Stock Tumbles As Hopes For Muscular Dystrophy Drug Dim
04:43PM  U.S. Stocks Edge Higher; U.S. Crude Oil Rises at
03:34PM  Stocks on edge, bonds up ahead of jobs report
02:12PM  Trending Tickers: SIG, SRPT, QLIK, WMT
01:11PM  Why Is Sarepta Therapeutics (SPRT) Stock Down 20% Today?
12:41PM  What the Heck Happened to Sarepta? at
12:38PM  Why AMD, Hovnanian, and Three Other Stocks Are Down Today at Insider Monkey
12:33PM  Sarepta Sinks on Speculation Over 'Compassionate Use' of Duchenne Drug
12:28PM  4 stocks, 4 trades: SRPT, BOX, JOY & UAL
11:44AM  Why Sarepta Therapeutics Shares Are Tumbling 19% Today at Motley Fool
11:04AM  Biotech Stocks: Are They Back? at Investopedia
10:37AM  Sarepta stock plummets 20% after FDA announces changes to investigational drug process at MarketWatch
09:30AM  The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
Jun-01-16 04:43PM  BioMarin Stock Slides After Muscular-Dystrophy Drug Shelved
03:20PM  One Reason Why Sarepta (SRPT) Stock Is Climbing Today
02:40PM  Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
10:21AM  Why BioMarin's Bad News is Great for Sarepta at
09:15AM  Premarket Technical Breakdown Highlights on Biotech Stocks
May-31-16 04:18PM  IBB Rose 0.9% before the Long Weekend
May-27-16 08:43AM  Is the FDAs decision to delay Sarepta drug decision good or bad? Nobody really knows at MarketWatch
08:33AM  Delayed FDA Decision Sends Sarepta Therapeutics Soaring
May-26-16 02:35PM  Sarepta: What the Bulls Say at
10:52AM  Sarepta: We've Seen This Before at
08:01AM  Trending Now: SRPT
12:11AM  [$$] Muscular Dystrophy Day at the FDA at The Wall Street Journal
May-25-16 09:16PM  [$$] Business Watch at The Wall Street Journal +26.63%
08:46PM  Should Investors Be Excited About Sarepta's Delay? at Motley Fool
07:38PM  [$$] Muscular Dystrophy Day at the FDA at The Wall Street Journal
06:48PM  Trade school: how to take advantage of weekly options at CNBC
05:41PM  Sarepta shares soar on FDA's eteplirsen review delay at CNBC
05:21PM  Why Computer Sciences, Sarepta Therapeutics, and Nimble Storage Jumped Today at Motley Fool
04:27PM  [$$] Sarepta Jumps on FDA Delay but Remains a Buy at
04:12PM  [$$] Sarepta: FDA's Decision on Dystrophy Drug Delayed at The Wall Street Journal
04:02PM  Sarepta Gets Second Wind, As FDA Delays Drug Decision Again
03:56PM  Sarepta (SRPT) Stock Spikes After FDA Delayed Approval Decision
03:45PM  [$$] How Options Investors Can Profit From Sarepta at
03:20PM  Dow jumps triple digits as oil hits 2016 high
02:25PM  Here's How to Trade 7 of the Market's Most-Active Stocks Right Now
02:05PM  Sarepta Therapeutics: Is This Why the FDA Delayed Its Decision? at
01:35PM  Why is Sarepta Therapeutics (SRPT) Stock Soaring 20% Today?
01:35PM  Trending Tickers: SRPT, BABA, CSC, CHK, C
12:23PM  FDA delay raises slim hope for muscular dystrophy drug
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company's lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; and a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BEHRENS M KATHLEENDirectorMar 16Buy14.5410,000145,43321,855Mar 16 08:15 PM
BEHRENS M KATHLEENDirectorMar 14Buy16.5465,0001,075,276112,166Mar 16 08:15 PM
Barry RichardDirectorMar 14Buy15.6675,0001,174,1853,241,014Mar 16 08:09 PM